Dear Editor-in-Chief

Colon cancer commonly has distant metastasis to the liver, lung, lymph node, and bone; most pa-tients receive chemotherapy to block micrometas-tasis after surgery (1). As chemotherapy to treat colon cancer, the FOLFOX regimen, which com-bines folinic acid, fluorouracil, and oxaliplatin, is often used. Oxaliplatin, a platinum-based chemo-therapy drug, has been demonstrated to play an important role in increasing the survival of colon cancer patients and reducing the recurrence rate; however, as a chemotherapy drug that causes damage to the dorsal root ganglia, oxaliplatin is known to cause peripheral neuropathy in colon cancer patients (2). Chemotherapy-induced peripheral neuropathy is highly relevant to the safety of patients, such as with regard to fender-bender accidents, falls, and external wounds, and it generally lowers the ability to sustain ordinary life functions (3, 4). Most pre-vious studies focused on the occurrence of symp-toms, rather than a multi-dimensional and multi-factorial approach to the symptoms, so it is insuf-ficient for medical staff to understand merely the symptoms. Thus, this study sought to provide basic data for interventions according to the type of peripheral neuropathy for medical staff practi-tioners by understanding the symptoms of periph-eral neuropathy, based on the theory of un-pleasant symptoms, and understanding the influ-encing factors and functional status according to symptom type. This was a cross-sectional and descriptive research study. The subjects included 250 patients with colorectal cancer who were admitted to Kyun